Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
City of Hope Medical Center
With
OBJECTIVES: Primary * To determine the maximum tolerated dose of intensity-modulated total marrow and lymph node irradiation (TMLI) using helical tomotherapy in combination with a reduced-intensity preparative regimen comprising fludarabine phosphate and melphalan in patients undergoing allogeneic hematopoietic stem cell transplantation for advanced, relapsed or refractory hematological malignancies. * To describe the toxicities of escalating doses of TMLI in these patients. Secondary * To describe the frequency of clinical response in patients treated with this regimen. * To describe the frequency of primary and secondary engraftment failure in patients treated with this regimen. * To describe the time to neutrophil and platelet engraftment in patients treated with this regimen. * To describe the incidence of acute and chronic graft-versus-host disease in patients treated with this regimen. * To describe the overall survival of patients treated with this regimen. * To describe the progression-free survival of patients treated with this regimen. OUTLINE: This is a dose-escalation study of intensity-modulated total marrow and lymph node irradiation (TMLI). * Intensity-modulated radiation therapy: Patients undergo TMLI to skeletal bone/marrow, major lymph node chains, spleen, and liver using helical tomotherapy twice daily on days -6 to -3. * Reduced-intensity preparative regimen: Patients receive fludarabine phosphate IV on days -6 to -2 and melphalan IV on day -1. * Hematopoietic stem cell transplantation (HSCT): Patients undergo allogeneic HSCT on day 0. After completion of study treatment, patients are followed periodically.
Age
16–any
Sex
ALL
Healthy volunteers
Not accepted
